Severe parkinsonian symptom development on combination treatment with tacrine and haloperidol.
McSwain
M L
ML
Forman
L M
LM
D000368:Aged; D000369:Aged, 80 and over; D014150:Antipsychotic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D003704:Dementia / Q000188:drug therapy; D004359:Drug Therapy, Combination; D006220:Haloperidol / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D008297:Male; D018697:Nootropic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D010302:Parkinson Disease, Secondary / Q000139:chemically induced* / Q000503:physiopathology; D013619:Tacrine / Q000009:adverse effects* / Q000627:therapeutic use
D014150:Antipsychotic Agents; D018697:Nootropic Agents; D013619:Tacrine; D006220:Haloperidol